Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The UK Cystic Fibrosis Gene Therapy Consortium has been working towards clinical gene therapy for patients with cystic fibrosis for several years. We have recently embarked on a large, multi-dose clinical trial of a non-viral, liposome-based formulation powered for the first time to detect clinical benefit. The article describes the details of the protocol.

Original publication

DOI

10.1136/thoraxjnl-2013-203309

Type

Journal article

Journal

Thorax

Publication Date

11/2013

Volume

68

Pages

1075 - 1077

Keywords

Cystic Fibrosis, Cystic Fibrosis, Cystic Fibrosis Transmembrane Conductance Regulator, Double-Blind Method, Follow-Up Studies, Genetic Therapy, Humans, Prospective Studies, Treatment Outcome